» Authors » Richard Malley

Richard Malley

Explore the profile of Richard Malley including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 119
Citations 3997
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Borys D, Smulders R, Haranaka M, Nakano T, Chichili G, Ebara M, et al.
Vaccine . 2024 Nov; 44:126545. PMID: 39612802
Background: The burden of pneumococcal diseases remains high in Japan. Pn-MAPS24v is a novel MAPS-based vaccine containing complexes of 24 serotype-specific polysaccharides (PS), non-covalently coupled with fusion protein 1 (CP1)....
2.
Boerth E, Gong J, Roffler B, Hancock Z, Berger L, Song B, et al.
Vaccines (Basel) . 2024 Oct; 12(10). PMID: 39460258
Background: Shigellosis is the leading cause of diarrheal deaths worldwide and is particularly dangerous in children under 5 years of age in low- and middle-income countries. Additionally, the rise in...
3.
Gent V, Lu Y, Lukhele S, Dhar N, Dangor Z, Hosken N, et al.
Sci Rep . 2024 Sep; 14(1):22665. PMID: 39349584
Group B Streptococcus (GBS) is a major cause of pneumonia, sepsis, and meningitis in infants younger than 3 months of age. Furthermore, GBS infection in pregnant women is associated with...
4.
Stanley S, Silva-Costa C, Gomes-Silva J, Melo-Cristino J, Malley R, Ramirez M
medRxiv . 2024 Sep; PMID: 39252931
Background Clonal complex 180 (CC180) is currently the major clone of serotype 3 Streptococcus pneumoniae (Spn). The 13-valent pneumococcal conjugate vaccine (PCV13) does not have significant efficacy against serotype 3...
5.
Chichili G, Smulders R, Santos V, Cywin B, Kovanda L, Van Sant C, et al.
Vaccine . 2024 Jun; 42(23):126023. PMID: 38897894
No abstract available.
6.
Bloom D, Pecetta S, Scorza F, Carfi A, Carleton B, Cipriano M, et al.
Sci Transl Med . 2024 May; 16(745):eadm9183. PMID: 38691620
As the world's population grows older, vaccination is becoming a key strategy for promoting healthy aging. Despite scientific progress in adult vaccine development, obstacles such as immunosenescence and vaccine hesitancy...
7.
Funk A, Florin T, Kuppermann N, Finkelstein Y, Kazakoff A, Baldovsky M, et al.
Clin Infect Dis . 2024 Mar; 78(6):1522-1530. PMID: 38530249
Background: Asymptomatic SARS-CoV-2 infection in children is highly prevalent but its acute and chronic implications have been minimally described. Methods: In this controlled case-ascertained household transmission study, we recruited asymptomatic...
8.
Florin T, Freedman S, Xie J, Funk A, Tancredi D, Kim K, et al.
J Pediatric Infect Dis Soc . 2024 Feb; 13(4):257-259. PMID: 38391389
No abstract available.
9.
Borys D, Rupp R, Smulders R, Chichili G, Kovanda L, Santos V, et al.
Vaccine . 2024 Feb; 42(10):2560-2571. PMID: 38360475
Background: Pneumococcal conjugate vaccines (PCVs) significantly reduced pneumococcal disease burden. Nevertheless, alternative approaches for controlling more serotypes are needed. Here, the safety, tolerability, and immunogenicity of a 24-valent (1/2/3/4/5/6A/6B/7F/8/9N/9V/10A/11A/12F/14/15B/17F/18C/19A/19F/20B/22F/23F/33F) pneumococcal...
10.
Manning J, Manna S, Dunne E, Bongcaron V, Pell C, Patterson N, et al.
Vaccine . 2024 Feb; 42(7):1714-1722. PMID: 38350767
Pneumococcal Conjugate Vaccines (PCVs) have substantially reduced the burden of disease caused by Streptococcus pneumoniae (the pneumococcus). However, protection is limited to vaccine serotypes, and when administered to children who...